Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
22 3월 2023 - 5:05AM
Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on
transforming medicines to transform lives, today announced that the
Compensation Committee of Avadel’s Board of Directors approved the
grant of non-statutory options to one (1) new employee to purchase
15,000 ordinary shares under Avadel’s 2021 Inducement Plan. The
awards were granted as an inducement material to the employee’s
acceptance of employment with Avadel in accordance with Nasdaq
Listing Rule 5635(c)(4). The options have a ten-year term and vest
over four years, with 25% vesting on the one-year anniversary of
the grant date and 25% on each anniversary thereafter. The options
are subject to the terms and conditions of Avadel’s 2021 Inducement
Plan approved by the Board of Directors in November 2021 and the
terms and conditions of award agreements covering the grants.
About Avadel Pharmaceuticals plcAvadel
Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical
company focused on transforming medicines to transform lives. Our
approach includes applying innovative solutions to the development
of medications that address the challenges patients face with
current treatment options. Our current lead drug candidate,
LUMRYZ™, is an investigational formulation of sodium oxybate
leveraging our proprietary drug delivery technology and designed to
be taken once at bedtime for the treatment of cataplexy or
excessive daytime sleepiness in adults with narcolepsy. For more
information, please visit www.avadel.com.
Investor Contact:Courtney TurianoStern Investor
Relations, Inc.Courtney.Turiano@sternir.com(212)
698-8687
Media Contact:Gabriella GreigReal
Chemistryggreig@realchemistry.com(203)
249-2688
Avadel Pharmaceuticals (NASDAQ:AVDL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Avadel Pharmaceuticals (NASDAQ:AVDL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024